Imminent recovery for multiplexes pushed to FY23 by Covid 3rd wave: Report

Icra said the revenues in the December quarter are expected to be the highest since the onset of the pandemic

Cinema, theatres, Multiplexes, Covid, coronavirus
Photo: PTI/Ravi Choudhary
Press Trust of India Mumbai
2 min read Last Updated : Jan 21 2022 | 8:34 PM IST

The ongoing third wave of the COVID pandemic will push back the imminent recovery for multiplex operators to first quarter of next fiscal, a domestic rating agency said on Friday.

It can be noted that in order to arrest the surge in new cases, many states have adopted measures including shutting down of cinema halls if not imposing full lockdown.

Icra said the revenues in the December quarter are expected to be the highest since the onset of the pandemic but the same will drop in the last quarter of the fiscal.

Once the restrictions are removed, the recovery is expected to be much faster, it said, noting that there is a robust content line-up of releases waiting in queue.

The industry participants were pinning recovery hopes on the festive season in Q3 FY22 with the strong content pipeline, increased pace of vaccination and relaxations in key markets like Maharashtra adding to the optimism, the agency's sector head for corporate sector ratings Jay Sheth said.

He added that supported by higher occupancy of over 60 per cent of pre-Covid levels, higher average ticket prices and spend per head, the multiplex operators are expected to report their highest revenues since Q4 FY2020) and report operating profits.

This is despite some restriction on occupancies in key states of Gujarat (60 per cent cap) and Maharashtra (50 per cent cap) and restrictions on consumption of food and beverages inside cinema halls (a high-margin segment) across a few key territories such as Maharashtra. Furthermore, as occupancy remained sub-optimal, contribution from another high-margin revenue source viz. advertising income (comprising 10-11 per cent of overall revenues) also remained low, he said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineCoronavirus Tests

First Published: Jan 21 2022 | 8:34 PM IST

Next Story